Market News
Global Sequencing Consumables Market- Recent Developments
Key Developments
- On July 5, 2023, QIAGEN, one of the leading global providers of Sample to Insight solutions announced the launch of the QIAseq Normalizer Kits that gives researchers a fast, convenient, and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs
- In November 2022, Element Biosciences, Inc., a developer of an innovative DNA sequencing platform disrupting the genomics industry, announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument
- In October 2022, PacBio, one of the leading developer of high-quality, highly accurate sequencing solutions, announced the launch of Revio long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology
Business Development Activities by the Market Players
- On October 16, 2023, Revvity, Inc., life science and Diagnostics Company and Element Biosciences, Inc., multi-disciplinary startup focused on innovating genetic analysis tools for the research market. announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples
- On August 7, 2023, PacBio, one of the leading developer of high-quality, highly accurate sequencing solutions and GeneDx, one of the leader in delivering improved health outcomes through genomic and clinical insights announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.
- On May 9, 2023, Thermo Fisher Scientific, analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services company and Pfizer, one of the global pharmaceutical company announced that they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East, and Asia Pacific where advanced genomic testing has previously been limited or unavailable.